期刊
MOLECULAR GENETICS AND METABOLISM
卷 124, 期 2, 页码 161-167出版社
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.ymgme.2018.04.002
关键词
Congenital manganism; SLC39A14; Manganese toxicity
资金
- American Academy of Pediatrics (AAP)
- Agency for Toxic Substances and Disease Registry (ATSDR) [FAIN: 1U61TS000237-02]
- U.S. Environmental Protection Agency (EPA) [DW-75-95877701]
- NIGMS [T32GM007753]
- NIH/NIAMS [1R01AR068429-01]
- NICHD/NHGRI/NIH [U19HD077671]
- NIH/NIEHS [1R01ES014638, P01 ES000002]
Congenital disorders of manganese metabolism are rare occurrences in children, and medical management of these disorders is complex and challenging. Homozygous exonic mutations in the manganese transporter SLC39A14 have recently been associated with a pediatric-onset neurodegenerative disorder characterized by brain manganese accumulation and clinical signs of manganese neurotoxicity, including parkinsonism-dystonia. We performed whole exome sequencing on DNA samples from two unrelated female children from the United Arab Emirates with progressive movement disorder and brain mineralization, identified a novel homozygous intronic mutation in SLC39A14 in both children, and demonstrated that the mutation leads to aberrant splicing. Both children had consistently elevated serum manganese levels and were diagnosed with SLC39A14-associated manganism. Over a four-year period, we utilized a multidisciplinary management approach for Patient 1 combining decreased manganese dietary intake and chelation with symptomatic management of dystonia. Our treatment strategy appeared to slow disease progression, but did not lead to a cure or reversal of already established deficits. Clinicians should consider testing for noncoding mutations in the diagnosis of congenital disorders of manganese metabolism and utilizing multidisciplinary approaches in the management of these disorders.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据